Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Differential effects of corticosteroids and anti-TNF on tumor-specific immune responses: implications for the management of irAEs.

Draghi A, Borch TH, Radic HD, Chamberlain CA, Gokuldass A, Svane IM, Donia M.

Int J Cancer. 2019 Sep 1;145(5):1408-1413. doi: 10.1002/ijc.32080. Epub 2019 Jan 7.

PMID:
30575963
2.

Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study.

Pedersen M, Westergaard MCW, Milne K, Nielsen M, Borch TH, Poulsen LG, Hendel HW, Kennedy M, Briggs G, Ledoux S, Nøttrup TJ, Andersen P, Hasselager T, Met Ö, Nelson BH, Donia M, Svane IM.

Oncoimmunology. 2018 Sep 26;7(12):e1502905. doi: 10.1080/2162402X.2018.1502905. eCollection 2018.

3.

T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression.

Andersen R, Borch TH, Draghi A, Gokuldass A, Rana MAH, Pedersen M, Nielsen M, Kongsted P, Kjeldsen JW, Westergaard MCW, Radic HD, Chamberlain CA, Hölmich LR, Hendel HW, Larsen MS, Met Ö, Svane IM, Donia M.

Ann Oncol. 2018 Jul 1;29(7):1575-1581. doi: 10.1093/annonc/mdy139.

PMID:
29688262
4.

Cancer immunotherapy in patients with brain metastases.

Caponnetto S, Draghi A, Borch TH, Nuti M, Cortesi E, Svane IM, Donia M.

Cancer Immunol Immunother. 2018 May;67(5):703-711. doi: 10.1007/s00262-018-2146-8. Epub 2018 Mar 8. Review.

PMID:
29520474
5.

Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: A randomized phase II study.

Kongsted P, Borch TH, Ellebaek E, Iversen TZ, Andersen R, Met Ö, Hansen M, Lindberg H, Sengeløv L, Svane IM.

Cytotherapy. 2017 Apr;19(4):500-513. doi: 10.1016/j.jcyt.2017.01.007. Epub 2017 Feb 15.

PMID:
28215654
6.

mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma.

Borch TH, Engell-Noerregaard L, Zeeberg Iversen T, Ellebaek E, Met Ö, Hansen M, Andersen MH, Thor Straten P, Svane IM.

Oncoimmunology. 2016 Jul 8;5(9):e1207842. eCollection 2016.

7.

PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine.

Munir Ahmad S, Martinenaite E, Hansen M, Junker N, Borch TH, Met Ö, Donia M, Svane IM, Andersen MH.

Oncoimmunology. 2016 Jul 1;5(8):e1202391. doi: 10.1080/2162402X.2016.1202391. eCollection 2016 Aug.

8.

Immune Monitoring Using mRNA-Transfected Dendritic Cells.

Borch TH, Svane IM, Met Ö.

Methods Mol Biol. 2016;1428:245-59. doi: 10.1007/978-1-4939-3625-0_16.

PMID:
27236804
9.

Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen.

Andersen R, Donia M, Ellebaek E, Borch TH, Kongsted P, Iversen TZ, Hölmich LR, Hendel HW, Met Ö, Andersen MH, Thor Straten P, Svane IM.

Clin Cancer Res. 2016 Aug 1;22(15):3734-45. doi: 10.1158/1078-0432.CCR-15-1879. Epub 2016 Mar 22.

10.

PD-L1-specific T cells.

Ahmad SM, Borch TH, Hansen M, Andersen MH.

Cancer Immunol Immunother. 2016 Jul;65(7):797-804. doi: 10.1007/s00262-015-1783-4. Epub 2016 Jan 2. Review.

PMID:
26724936
11.

Reorienting the immune system in the treatment of cancer by using anti-PD-1 and anti-PD-L1 antibodies.

Borch TH, Donia M, Andersen MH, Svane IM.

Drug Discov Today. 2015 Sep;20(9):1127-34. doi: 10.1016/j.drudis.2015.07.003. Epub 2015 Jul 17. Review.

PMID:
26189934

Supplemental Content

Loading ...
Support Center